Regulatory · source year

2019 regulatory records

49 selected, source-linked regulatory records dated 2019. This is selective source coverage, not a complete timeline.

Dated records

49 selected records.

Peptide profiles

24 connected profiles.

Cited sources

49 distinct public records.

Cited chronology

Dated source records

All record types in 2019 →

December 2019

5 records

November 2019

7 records

Semaglutide

Federal Register notice 2019-25850

The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

October 2019

3 records

September 2019

6 records

Plecanatide

Federal Register notice 2019-20108

The Federal Register published notice 2019-20108, attributed to FDA and its parent HHS department, on 2019-09-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Plecanatide.

Source: Federal Register via GovInfo ↗

→

Calcitonin salmon

Federal Register notice 2019-19347

The Federal Register published notice 2019-19347, attributed to FDA and its parent HHS department, on 2019-09-09. Its official title is “Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

Vasopressin

Federal Register notice 2019-18932

The Federal Register published notice 2019-18932, attributed to FDA and its parent HHS department, on 2019-09-03. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

August 2019

2 records

July 2019

5 records

June 2019

5 records

May 2019

4 records

Leuprolide

Federal Register notice 2019-11243

The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

Desmopressin

Federal Register notice 2019-10165

The Federal Register published notice 2019-10165, attributed to FDA and its parent HHS department, on 2019-05-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Dalbavancin

Federal Register notice 2019-09007

The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→

April 2019

1 record

Daptomycin

Federal Register notice 2019-06385

The Federal Register published notice 2019-06385, attributed to FDA and its parent HHS department, on 2019-04-02. Its official title is “Post-Marketing Pediatric-Focused Product Safety Reviews; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

March 2019

5 records

Oxytocin

Federal Register rule 2019-04226

The Federal Register published rule 2019-04226, attributed to FDA and its parent HHS department, on 2019-03-13. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

Vasopressin

Federal Register notice 2019-03810

The Federal Register published notice 2019-03810, attributed to FDA and its parent HHS department, on 2019-03-04. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

February 2019

3 records

Daptomycin

Federal Register notice 2019-03129

The Federal Register published notice 2019-03129, attributed to FDA and its parent HHS department, on 2019-02-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

Peginesatide

Federal Register notice 2019-02146

The Federal Register published notice 2019-02146, attributed to FDA and its parent HHS department, on 2019-02-13. Its official title is “Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

Source: Federal Register via GovInfo ↗

→

January 2019

3 records